# Assembly Biosciences, Inc.: overview ASMB · Nasdaq · CIK 1426800 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/asmb.md) · [Financials](/companies/asmb/financials.md) · [Filings](/companies/asmb/filings.md) · [Insiders](/companies/asmb/insiders.md) Latest reported revenue: [$13.4m](/filings/0001193125-26-349236.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-349236). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.8](/filings/0001193125-25-274277.md) | [7.4 d](/filings/0001193125-26-115992.md) | [9.4](/filings/0001193125-26-211987.md) | [9.6](/filings/0001193125-26-349236.md) | [10.8](/filings/0001193125-25-274277.md) | [42.5 d](/filings/0001193125-26-115992.md) | [8.2](/filings/0001193125-26-211987.md) | [13.4](/filings/0001193125-26-349236.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(160.1%)](/filings/0001193125-25-274277.md) | [(156.7%) d](/filings/0001193125-26-115992.md) | [(105.5%)](/filings/0001193125-26-211987.md) | [(115.2%)](/filings/0001193125-26-349236.md) | [(100.9%)](/filings/0001193125-25-274277.md) | [46.6% d](/filings/0001193125-26-115992.md) | [(138.4%)](/filings/0001193125-26-211987.md) | [(47.4%)](/filings/0001193125-26-349236.md) | | Net margin | % | [(140.4%)](/filings/0001193125-25-274277.md) | [(140.5%) d](/filings/0001193125-26-115992.md) | [(93.6%)](/filings/0001193125-26-211987.md) | [(105.9%)](/filings/0001193125-26-349236.md) | [(85.2%)](/filings/0001193125-25-274277.md) | [52.0% d](/filings/0001193125-26-115992.md) | [(110.5%)](/filings/0001193125-26-211987.md) | [(28.8%)](/filings/0001193125-26-349236.md) | | Diluted EPS | $ per share | [(1.51)](/filings/0001193125-25-274277.md) | not reported | [(1.17)](/filings/0001193125-26-211987.md) | [(1.33)](/filings/0001193125-26-349236.md) | [(0.72)](/filings/0001193125-25-274277.md) | not reported | [(0.54)](/filings/0001193125-26-211987.md) | [(0.20)](/filings/0001193125-26-349236.md) | | Free cash flow | $m | [(15.2) d](/filings/0001193125-25-274277.md) | [(0.4) d](/filings/0001193125-26-115992.md) | [(23.4)](/filings/0001193125-26-211987.md) | [(16.8) d](/filings/0001193125-26-349236.md) | [(15.2) d](/filings/0001193125-25-274277.md) | [14.2 d](/filings/0001193125-26-115992.md) | [(22.1)](/filings/0001193125-26-211987.md) | [(15.5) d](/filings/0001193125-26-349236.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.3](/filings/0000950170-23-009184.md) | [0.0](/filings/0000950170-24-038057.md) | [7.2](/filings/0000950170-25-042673.md) | [28.5](/filings/0001193125-26-115992.md) | [72.3](/filings/0001193125-26-115992.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2121.7%)](/filings/0000950170-23-009184.md) | not reported | [(902.5%)](/filings/0000950170-25-042673.md) | [(159.3%)](/filings/0001193125-26-115992.md) | [(16.8%)](/filings/0001193125-26-115992.md) | | Net margin | % | [(2076.4%)](/filings/0000950170-23-009184.md) | not reported | [(854.8%)](/filings/0000950170-25-042673.md) | [(140.9%)](/filings/0001193125-26-115992.md) | [(8.5%)](/filings/0001193125-26-115992.md) | | Diluted EPS | $ per share | [(3.00)](/filings/0000950170-23-009184.md) | [(23.08)](/filings/0000950170-24-038057.md) | [(13.38)](/filings/0000950170-25-042673.md) | [(6.69)](/filings/0001193125-26-115992.md) | [(0.55)](/filings/0001193125-26-115992.md) | | Free cash flow | $m | [(96.5)](/filings/0000950170-23-009184.md) | [(84.6)](/filings/0000950170-24-038057.md) | [22.5](/filings/0000950170-25-042673.md) | [(51.1)](/filings/0001193125-26-115992.md) | [(41.2)](/filings/0001193125-26-115992.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/asmb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GILEAD SCIENCES, INC.](/funds/882095.md) | 2026-06-30 | $136.8m | 4,977,089 | | Added +471,698 | | [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $44.1m | 1,604,590 | | Added +377,000 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $42.7m | 1,553,748 | | Added +888,497 | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $38.9m | 1,415,000 | | Added +415,000 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $28.0m | 1,020,410 | | Unchanged | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $23.5m | 849,309 | | Not compared | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $23.4m | 849,309 | | Not compared | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $21.1m | 766,819 | | Added +564,076 | | [Parkman Healthcare Partners LLC](/funds/1777015.md) | 2026-06-30 | $19.8m | 721,181 | | Added +309,954 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $15.4m | 558,942 | | Added +68,495 | ## Recent filings [All 863 filings](/companies/asmb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 16:05 ET | [8-K/A](/filings/0001193125-26-352193.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-352193 | | 2026-08-13 | 16:15 ET | [10-Q](/filings/0001193125-26-349236.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349236 | | 2026-08-13 | 16:11 ET | [8-K](/filings/0001193125-26-349198.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001193125-26-349198 | | 2026-06-05 | 16:00 ET | [8-K](/filings/0001193125-26-259481.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-259481 | | 2026-05-26 | 16:10 ET | [8-K](/filings/0001193125-26-239277.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-239277 | | 2026-05-22 | 07:15 ET | [8-K](/filings/0001193125-26-235469.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-235469 | | 2026-05-07 | 16:17 ET | [10-Q](/filings/0001193125-26-211987.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211987 | | 2026-05-07 | 16:12 ET | [8-K](/filings/0001193125-26-211922.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211922 | | 2026-04-22 | 16:12 ET | [DEF 14A](/filings/0001193125-26-170417.md) | Proxy statement, period 2026-06-04 | 0001193125-26-170417 | | 2026-03-30 | 17:32 ET | [8-K](/filings/0001193125-26-131872.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-131872 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-115992.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9c5ef521-52dc-4c29-8e6f-afe96caf1fa4) ## About the filer - CIK: 1426800 - Tickers: ASMB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.